Abstract 120P
Background
The prognostic importance of platelet-to-lymphocyte ratio(PLR)has been also investigated in some cancer types including colorectal cancer (CRC).Several studies have found that PLR is associated with poor prognosis in patients with CRC,but,the results are controversial.The aim of this study was to investigate the predictive and prognostic value of PLR,and the relationship between PLR and tumor localization.
Methods
A total of 201 patients with metastatic CRC and candidate to systemic treatments were retrospectively analyzed.Pretreatment complete blood cell count was evaluated to calculate PLR.The cutoff value for PLR was defined by the receiver operating characteristic(ROC)curve analysis and threshold value of 205.5 as best cut-off value was found.The prognostic and predictive significance of PLR was evaluated by univariate and logistic regression analysis.
Results
Significant relationship was detected between PLR and BRAF mutation,tumor localization.The higher rate of BRAF mutation was significantly detected for patients with PLRhigh(> 205.5)compared to those with PLRlow(<205.5)(p = 0.006).In addition,PLR was significantly higher in tumors located on the right colon than those with tumor on the left colon(p = 0.026).PLR, the presence of the primary tumor surgery, tumor localization, the presence of metastasectomy for progression-free survival(PFS)andPLR,age, BRAF mutation and the type of targeted therapy for overall survival(OS)were found to be prognostic factors by univariate analysis.Moreover,a logistic regression analysis indicated that PLR and the presence of metastasectomy were found to be an independent factors for predicting response to systemic treatment(p < 0.001,OR:0.30, 95%CI 0.16-0.34 and p = 0.020,OR: 0.40,95%CI 0.18-0.38,respectively).
Conclusions
Our results showed that pretreatment PLR was readily feasible and simple biomarker predicting response to treatment and survival,in addition it was significantly associated with tumor localization for patients with metastatic CRC.PLR may reflect immunogenic phenotype of patients with CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract